| Citation: |
Department of Medical Administration, National Health Commission of the People's Republic of China. Chinese Guidelines for the Clinical Management of Obesity (2024 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 90-108. DOI: 10.12290/xhyxzz.2024-0918
|
Obesity serves as a significant contributing factor to various chronic diseases, so standardized and systematic clinical management of obesity is crucial for enhancing overall health outcomes. Currently, there is a lack of comprehensive and authoritative guidelines for the diagnosis and treatment of obesity. Based on existing high-quality evidence-based medical literature, this guideline, by integrating multidisciplinary expert opinions, systematically addresses the etiology, epidemiology, definition, diagnostic criteria, treatment principles, and multi-disciplinary treatment models for obesity. Its objective is to standardize the clinical management of obesity in China and effectively guide healthcare professionals across various medical institutions. Furthermore, this guideline will be continually updated and refined based on emerging clinical evidence.
| [1] |
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223-1249. DOI: 10.1016/S0140-6736(20)30752-2
|
| [2] |
Loos R, Yeo G. The genetics of obesity: from discovery to biology[J]. Nat Rev Genet, 2022, 23(2): 120-133. DOI: 10.1038/s41576-021-00414-z
|
| [3] |
Pan X F, Wang L, Pan A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(6): 373-392. DOI: 10.1016/S2213-8587(21)00045-0
|
| [4] |
Müller H L, Tauber M, Lawson E A, et al. Hypothalamic syndrome[J]. Nat Rev Dis Primers, 2022, 8(1): 24. DOI: 10.1038/s41572-022-00351-z
|
| [5] |
Rosen C J. Antagonizing the leptin receptor in obesity[J]. N Engl J Med, 2023, 388(24): 2291-2293. DOI: 10.1056/NEJMe2301915
|
| [6] |
Lei Y, Liang X, Sun Y, et al. Region-specific transcriptomic responses to obesity and diabetes in macaque hypothalamus[J]. Cell Metab, 2024, 36(2): 438-453. DOI: 10.1016/j.cmet.2024.01.003
|
| [7] |
Wu Q, Liang X, Wang K, et al. Intestinal hypoxia-inducible factor 2a regulates lactate levels to shape the gut microbiome and alter thermogenesis[J]. Cell Metab, 2021, 33(10): 1988-2003. DOI: 10.1016/j.cmet.2021.07.007
|
| [8] |
Huang X, Li X, Shen H, et al. Transcriptional repression of beige fat innervation via a YAP/TAZ-S100B axis[J]. Nat Commun, 2023, 14(1): 7102. DOI: 10.1038/s41467-023-43021-8
|
| [9] |
Wells J C, Sawaya A L, Wibaek R, et al. The double burden of malnutrition: aetiological pathways and consequences for health[J]. Lancet, 2020, 395(10217): 75-88. DOI: 10.1016/S0140-6736(19)32472-9
|
| [10] |
Li V, He Y, Contrepois K, et al. An exercise-inducible metabolite that suppresses feeding and obesity[J]. Nature, 2022, 606(7915): 785-790. DOI: 10.1038/s41586-022-04828-5
|
| [11] |
Chow L S, Gerszten R E, Taylor J M, et al. Exerkines in health, resilience and disease[J]. Nat Rev Endocrinol, 2022, 18(5): 273-289. DOI: 10.1038/s41574-022-00641-2
|
| [12] |
Russell G, Lightman S. The human stress response[J]. Nat Rev Endocrinol, 2019, 15(9): 525-534. DOI: 10.1038/s41574-019-0228-0
|
| [13] |
Scherer T, Sakamoto K, Buettner C. Brain insulin signalling in metabolic homeostasis and disease[J]. Nat Rev Endocrinol, 2021, 17(8): 468-483. DOI: 10.1038/s41574-021-00498-x
|
| [14] |
Chaput J P, McHill A W, Cox R C, et al. The role of insufficient sleep and circadian misalignment in obesity[J]. Nat Rev Endocrinol, 2023, 19(2): 82-97. DOI: 10.1038/s41574-022-00747-7
|
| [15] |
Tomlinson J W, Tchernof A S. On steroids in obesity and diabetes[J]. J Steroid Biochem Mol Biol, 2010, 122(1/3): 1-2.
|
| [16] |
Clutter W E. Screening for Cushing'S syndrome in an era of epidemic obesity[J]. Mo Med, 2011, 108(2): 104-106.
|
| [17] |
Göknar N, Webb H, Waters A, et al. Long-term obesity prevalence and linear growth in children with idiopathic nephrotic syndrome: is normal growth and weight control possible with steroid-sparing drugs and low-dose steroids for relapses?[J]. Pediatr Nephrol, 2022, 37(7): 1575-1584. DOI: 10.1007/s00467-021-05288-1
|
| [18] |
Wang K, Zhang Z, Hang J, et al. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target[J]. Science, 2023, 381(6657): eadd5787. DOI: 10.1126/science.add5787
|
| [19] |
Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461. DOI: 10.1016/S2213-8587(21)00118-2
|
| [20] |
中华人民共和国国务院新闻办公室. 国务院新闻办就《中国居民营养与慢性病状况报告(2020年)》有关情况举行发布会[EB/OL]. (2020-12-24)[2024-12-05]. http://www.gov.cn/xinwen/2020-12/24/content_5572983.htm.
State Council Information Office of the People's Republic of China. The State Council Information Office held a press conference on the report on the nutrition and chronic disease status of Chinese residents (2020)[EB/OL]. (2020-12-24)[2024-12-05]. http://www.gov.cn/xinwen/2020-12/24/content_5572983.htm.
|
| [21] |
Wang L, Zhou B, Zhao Z, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18[J]. Lancet, 2021, 398(10294): 53-63. DOI: 10.1016/S0140-6736(21)00798-4
|
| [22] |
Chen K, Shen Z, Gu W, et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults[J]. Diabetes Obes Metab, 2023, 25(11): 3390-3399. DOI: 10.1111/dom.15238
|
| [23] |
Obesity: preventing and managing the global epidemic. Report of a WHO consultation[J]. World Health Organ Tech Rep Ser, 2000, 894: 1-253.
|
| [24] |
Shi H, Clegg D J. Sex differences in the regulation of body weight[J]. Physiol Behav, 2009, 97(2): 199-204. DOI: 10.1016/j.physbeh.2009.02.017
|
| [25] |
Mechanick J I, Hurley D L, Garvey W T. Adiposity-based chronic disease as a new diagnostic term: the american association of clinical endocrinologists and american college of endocrinology position statement[J]. Endocr Pract, 2017, 23(3): 372-378. DOI: 10.4158/EP161688.PS
|
| [26] |
Norgan N G, Ferro-Luzzi A. Weight-height indices as estimators of fatness in men[J]. Hum Nutr Clin Nutr, 1982, 36(5): 363-372. http://europepmc.org/abstract/MED/7174359
|
| [27] |
Keys A, Fidanza F, Karvonen M J, et al. Indices of relative weight and obesity[J]. Int J Epidemiol, 2014, 43(3): 655-665. DOI: 10.1093/ije/dyu058
|
| [28] |
Manson J E, Willett W C, Stampfer M J, et al. Body weight and mortality among women[J]. N Engl J Med, 1995, 333(11): 677-685. DOI: 10.1056/NEJM199509143331101
|
| [29] |
Wang Y, Monteiro C, Popkin B M. Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia[J]. Am J Clin Nutr, 2002, 75(6): 971-977. DOI: 10.1093/ajcn/75.6.971
|
| [30] |
中华人民共和国国家卫生和计划生育委员会. 成人体重判定: WS/T 428-2013[S]. 北京: 中国标准出版社, 2013.
National Health and Family Planning Commission of the People's Republic of China. Criteria of weight for adults: WS/T 428-2013[S]. Beijing: Standards Press of China, 2013.
|
| [31] |
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet, 2004, 363(9403): 157-163. DOI: 10.1016/S0140-6736(03)15268-3
|
| [32] |
Garvey W T, Mechanick J I, Brett E M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive clinical practice guidelines for medical care of patients with obesity[J]. Endocr Pract, 2016, 22(S3): 1-203.
|
| [33] |
Müller M J, Braun W, Enderle J, et al. Beyond BMI: conceptual issues related to overweight and obese patients[J]. Obes Facts, 2016, 9(3): 193-205. DOI: 10.1159/000445380
|
| [34] |
Neeland I J, Ross R, Despres J P, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement[J]. Lancet Diabetes Endocrinol, 2019, 7(9): 715-725. DOI: 10.1016/S2213-8587(19)30084-1
|
| [35] |
Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe[J]. N Engl J Med, 2008, 359(20): 2105-2120. DOI: 10.1056/NEJMoa0801891
|
| [36] |
World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation[R]. Geneva: World Health Organization, 2011.
|
| [37] |
Stevens J, Katz E G, Huxley R R. Associations between gender, age and waist circumference[J]. Eur J Clin Nutr, 2010, 64(1): 6-15. DOI: 10.1038/ejcn.2009.101
|
| [38] |
Brunani A, Perna S, Soranna D, et al. Body composition assessment using bioelectrical impedance analysis (BIA) in a wide cohort of patients affected with mild to severe obesity[J]. Clin Nutr, 2021, 40(6): 3973-3981. DOI: 10.1016/j.clnu.2021.04.033
|
| [39] |
Palmas F, Ciudin A, Guerra R, et al. Comparison of computed tomography and dual-energy X-ray absorptiometry in the evaluation of body composition in patients with obesity[J]. Front Endocrinol (Lausanne), 2023, 14: 1161116. DOI: 10.3389/fendo.2023.1161116
|
| [40] |
Lv H, Li M Y, Wang Z C, et al. Clinical practice guideline for body composition assessment based on upper abdominal magnetic resonance images annotated using artificial intelligence[J]. Chin Med J (Engl), 2022, 135(6): 631-633. DOI: 10.1097/CM9.0000000000002002
|
| [41] |
陈家伦. 临床内分泌学[M]. 上海: 上海科学技术出版社, 2011.
Chen J L. Clinical endocrinology[M]. Shanghai: Shanghai Scientific and Technical Publishers, 2011.
|
| [42] |
中华人民共和国国家卫生健康委员会. 7岁以下儿童生长标准: WS/T 423-2022[S]. 北京: 中国标准出版社, 2022.
National Health Commission of the People's Republic of China. Growth standard for children under 7 years of age: WS/T 423-2022[S]. Beijing: Standards Press of China, 2022.
|
| [43] |
中华人民共和国国家卫生和计划生育委员会. 学龄儿童青少年超重与肥胖筛查: WS/T 586-2018[S]. 北京: 中国标准出版社, 2018.
National Health and Family Planning Commission of the People's Republic of China. Screening for overweight and obesity among school-age children and adolescents: WS/T 586-2018[S]. Beijing: Standards Press of China, 2018.
|
| [44] |
Kalinderi K, Goula V, Sapountzi E, et al. Syndromic and monogenic obesity: new opportunities due to Genetic-Based pharmacological treatment[J]. Children (Basel), 2024, 11(2): 153. http://www.mdpi.com/2227-9067/11/2/153/html
|
| [45] |
中华医学会内分泌学分会, 中华中医药学会糖尿病分会, 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会, 等. 基于临床的肥胖症多学科诊疗共识(2021年版)[J]. 中华消化外科杂志, 2021, 20(11): 1137-1152. DOI: 10.3760/cma.j.cn115610-20210829-00422
Chinese Society of Endocrinology, Diabetes Society of China Association of Chinese Medicine, Chinese Society for Metabolic and Bariatric Surgery, et al. Multidisciplinary clinical consensus on diagnosis and treatment of obesity (2021 edition)[J]. Chin J Dig Surg, 2021, 20(11): 1137-1152. DOI: 10.3760/cma.j.cn115610-20210829-00422
|
| [46] |
Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: updates on pathophysiology and management in 2021[J]. Int J Mol Sci, 2022, 23(2): 786. DOI: 10.3390/ijms23020786
|
| [47] |
Preda A, Carbone F, Tirandi A, et al. Obesity phenotypes and cardiovascular risk: From pathophysiology to clinical management[J]. Rev Endocr Metab Disord, 2023, 24(5): 901-919. DOI: 10.1007/s11154-023-09813-5
|
| [48] |
Acosta A, Camilleri M, Abu D B, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic[J]. Obesity (Silver Spring), 2021, 29(4): 662-671. DOI: 10.1002/oby.23120
|
| [49] |
Hurtado A M, Acosta A. Precision medicine and obesity[J]. Gastroenterol Clin North Am, 2021, 50(1): 127-139. DOI: 10.1016/j.gtc.2020.10.005
|
| [50] |
Sacoto D, Hurtado M D, Acosta A. Precision medicine and obesity[J]. Handb Exp Pharmacol, 2022, 274: 467-485.
|
| [51] |
Sharma A M, Kushner R F. A proposed clinical staging system for obesity[J]. Int J Obes (Lond), 2009, 33(3): 289-295. DOI: 10.1038/ijo.2009.2
|
| [52] |
Guo F, Moellering D R, Garvey W T. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity[J]. Obesity (Silver Spring), 2014, 22(1): 110-118. DOI: 10.1002/oby.20585
|
| [53] |
Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997.
|
| [54] |
Kivimäki M, Kuosma E, Ferrie J E, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe[J]. Lancet Public Health, 2017, 2(6): e277-e285. DOI: 10.1016/S2468-2667(17)30074-9
|
| [55] |
Ndumele C E, Neeland I J, Tuttle K R, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association[J]. Circulation, 2023, 148(20): 1636-1664. DOI: 10.1161/CIR.0000000000001186
|
| [56] |
张弘玮, 狄建忠, 于浩泳, 等. 胃旁路术对糖尿病肾病蛋白尿影响的随访研究[J]. 外科理论与实践, 2015, 20(5): 399-402.
Zhang H W, Di J Z, Yu H Y, et al. Effect of gastric bypass on diabetic nephropathy with microalbuminuria: one year follow-up study[J]. J Surg Conc Pract, 2015, 20(5): 399-402.
|
| [57] |
Schauer P R, Bhatt D L, Kirwan J P, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-Year outcomes[J]. N Engl J Med, 2017, 376(7): 641-651. DOI: 10.1056/NEJMoa1600869
|
| [58] |
邹大进, 张征, 纪立农. 缓解2型糖尿病中国专家共识[J]. 中国糖尿病杂志, 2021, 29(9): 641-652.
Zou D J, Zhang Z, Ji L N. Consensus of chinese experts on the remission of type 2 diabetes mellitus[J]. Chin J Diabetes, 2021, 29(9): 641-652.
|
| [59] |
Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial[J]. Lancet, 2021, 397(10271): 293-304. DOI: 10.1016/S0140-6736(20)32649-0
|
| [60] |
Lean M E, Leslie W S, Barnes A C, et al. 5-Year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study[J]. Lancet Diabetes Endocrinol, 2024, 12(4): 233-246. DOI: 10.1016/S2213-8587(23)00385-6
|
| [61] |
Zhu J J, Zhang Y, Wu Y L, et al. Obesity and dyslipidemia in Chinese adults: a cross-sectional study in Shanghai, China[J]. Nutrients, 2022, 14(11): 2321. DOI: 10.3390/nu14112321
|
| [62] |
李梦伊, 刘雁军, 王桂琦, 等. 大中华减重与代谢手术数据库2023年度报告[J]. 中国实用外科杂志, 2024, 44(5): 552-563.
Li M Y, Liu Y J, Wang G Q, et al. Greater China metabolic and bariatric surgery database registry report(2023)[J]. Chin J Pract Surg, 2024, 44(5): 552-563.
|
| [63] |
Nussbaumerova B, Rosolova H. Obesity and dyslipidemia[J]. Curr Atheroscler Rep, 2023, 25(12): 947-955. DOI: 10.1007/s11883-023-01167-2
|
| [64] |
中华医学会心血管病学分会高血压学组. 肥胖相关性高血压管理的中国专家共识[J]. 中华心血管病杂志, 2016, 44(3): 212-219. DOI: 10.3760/cma.j.issn.0253-3758.2016.03.006
Hypertension Group, Cardiovascular Disease Branch, Chinese Medical Association. Chinese expert consensus on the management of obesity related hypertension[J]. Chin J Cardiol, 2016, 44(3): 212-219. DOI: 10.3760/cma.j.issn.0253-3758.2016.03.006
|
| [65] |
Hall M E, Cohen J B, Ard J D, et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association[J]. Hypertension, 2021, 78(5): e38-e50.
|
| [66] |
Kennedy C, Hayes P, Salama S, et al. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis[J]. J Clin Med, 2023, 12(3): 772. DOI: 10.3390/jcm12030772
|
| [67] |
Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program[J]. Cardiovasc Diabetol, 2023, 22(1): 66. DOI: 10.1186/s12933-023-01797-5
|
| [68] |
Schaffner F, Thaler H. Nonalcoholic fatty liver disease[J]. Prog Liver Dis, 1986, 8: 283-298. http://msu.edu/~ferrervl/NEJM/NEJMLBP/assets/NAFLD.pdf
|
| [69] |
Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367
|
| [70] |
Diehl A M, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072. DOI: 10.1056/NEJMra1503519
|
| [71] |
Quek J, Chan K E, Wong Z Y, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8(1): 20-30. DOI: 10.1016/S2468-1253(22)00317-X
|
| [72] |
Younossi Z, Anstee Q M, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109
|
| [73] |
Li M, Cao D, Liu Y, et al. Alterations in the liver fat fraction features examined by magnetic resonance imaging following bariatric surgery: a self-controlled observational study[J]. Obes Surg, 2020, 30(5): 1917-1928. DOI: 10.1007/s11695-020-04415-5
|
| [74] |
Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039
|
| [75] |
Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Ann Hepatol, 2024, 29(1): 101133. DOI: 10.1016/j.aohep.2023.101133
|
| [76] |
范建高, 李小英. NAFLD更名MAFLD、MASLD: 背景、异同、对策[J]. 中华肝脏病杂志, 2023, 31(8): 789-792. DOI: 10.3760/cma.j.cn501113-20230809-00042
Fan J G, Li X Y. NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures[J]. Chin J Hepatol, 2023, 31(8): 789-792. DOI: 10.3760/cma.j.cn501113-20230809-00042
|
| [77] |
Newsome P N, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. DOI: 10.1056/NEJMoa2028395
|
| [78] |
Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial[J]. Lancet, 2023, 401(10390): 1786-1797. DOI: 10.1016/S0140-6736(23)00634-7
|
| [79] |
Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients[J]. Gastroenterology, 2015, 149(2): 379-388. DOI: 10.1053/j.gastro.2015.04.014
|
| [80] |
Lassailly G, Caiazzo R, Ntandja-Wandji L C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis[J]. Gastroenterology, 2020, 159(4): 1290-1301.e5. DOI: 10.1053/j.gastro.2020.06.006
|
| [81] |
Frey W C, Pilcher J. Obstructive Sleep-Related breathing disorders in patients evaluated for bariatric surgery[J]. Obes Surg, 2003, 13(5): 676-683. DOI: 10.1381/096089203322509228
|
| [82] |
Sareli A E, Cantor C R, Williams N N, et al. Obstructive sleep apnea in patients undergoin bariatric surgery--a tertiary center experience[J]. Obes Surg, 2011, 21(3): 316-327. DOI: 10.1007/s11695-009-9928-1
|
| [83] |
Schwartz A R, Patil S P, Laffan A M, et al. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches[J]. Proc Am Thorac Soc, 2008, 5(2): 185-192. DOI: 10.1513/pats.200708-137MG
|
| [84] |
Lévy P, Kohler M, McNicholas W T, et al. Obstructive sleep apnoea syndrome[J]. Nat Rev Dis Primers, 2015, 1: 15015. DOI: 10.1038/nrdp.2015.15
|
| [85] |
Hernandez T L, Ballard R D, Weil K M, et al. Effects of maintained weight loss on sleep dynamics and neck morphology in severely obese adults[J]. Obesity (Silver Spring), 2009, 17(1): 84-91. DOI: 10.1038/oby.2008.485
|
| [86] |
Anandam A, Akinnusi M, Kufel T, et al. Effects of dietary weight loss on obstructive sleep apnea: a meta-analysis[J]. Sleep Breath, 2013, 17(1): 227-234. DOI: 10.1007/s11325-012-0677-3
|
| [87] |
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis[J]. JAMA, 2004, 292(14): 1724-1737. DOI: 10.1001/jama.292.14.1724
|
| [88] |
Yang R, Li Q, Zhou Z, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade[J]. Lancet Reg Health West Pac, 2022, 25: 100494.
|
| [89] |
Qi X, Yun C, Sun L, et al. Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome[J]. Nat Med, 2019, 25(8): 1225-1233. DOI: 10.1038/s41591-019-0509-0
|
| [90] |
Escobar-Morreale H F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14(5): 270-284. DOI: 10.1038/nrendo.2018.24
|
| [91] |
Odle A K, Akhter N, Syed M M, et al. Leptin regulation of gonadotrope gonadotropin-releasing hormone receptors as a metabolic checkpoint and gateway to reproductive competence[J]. Front Endocrinol (Lausanne), 2017, 8: 367.
|
| [92] |
Samarasinghe S, Woods C, Miras A D. Bariatric surgery in women with polycystic ovary syndrome[J]. Metabolism, 2024, 151: 155745. DOI: 10.1016/j.metabol.2023.155745
|
| [93] |
Jungheim E S, Travieso J L, Carson K R, et al. Obesity and reproductive function[J]. Obstet Gynecol Clin North Am, 2012, 39(4): 479-493. DOI: 10.1016/j.ogc.2012.09.002
|
| [94] |
Johansson K, Bodnar L M, Stephansson O, et al. Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study[J]. Lancet, 2024, 403(10435): 1472-1481. DOI: 10.1016/S0140-6736(24)00255-1
|
| [95] |
Håkonsen L B, Thulstrup A M, Aggerholm A S, et al. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men[J]. Reprod Health, 2011, 8: 24. DOI: 10.1186/1742-4755-8-24
|
| [96] |
柒锐冰, 陈冰, 李争明. 肥胖对男性生殖健康影响的研究进展[J]. 中华内分泌代谢杂志, 2023, 39(12): 1083-1088. DOI: 10.3760/cma.j.cn311282-20230511-00219
Qi R B, Chen B, Li Z M. Obesity and male reproductive health: an update[J]. Chin J Endocrinol Metab, 2023, 39(12): 1083-1088. DOI: 10.3760/cma.j.cn311282-20230511-00219
|
| [97] |
Poirier P, Giles T D, Bray G A, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism[J]. Circulation, 2006, 113(6): 898-918. DOI: 10.1161/CIRCULATIONAHA.106.171016
|
| [98] |
Lincoff A M, Brown-Frandsen K, Colhoun H M, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes[J]. N Engl J Med, 2023, 389(24): 2221-2232. DOI: 10.1056/NEJMoa2307563
|
| [99] |
Wanahita N, Messerli F H, Bangalore S, et al. Atrial fibrillation and obesity--results of a meta-analysis[J]. Am Heart J, 2008, 155(2): 310-315. DOI: 10.1016/j.ahj.2007.10.004
|
| [100] |
Parish D. Obesity and the risk of new-onset atrial fibrillation[J]. JAMA, 2005, 293(16): 1974. http://www.onacademic.com/detail/journal_1000037700834110_abd6.html
|
| [101] |
Joglar J A, Chung M K, Armbruster A L, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2024, 149(1): e1-e156. DOI: 10.1161/CIR.0000000000001208
|
| [102] |
Pandey A, LaMonte M, Klein L, et al. Relationship between physical activity, body mass index, and risk of heart failure[J]. J Am Coll Cardiol, 2017, 69(9): 1129-1142. DOI: 10.1016/j.jacc.2016.11.081
|
| [103] |
Kosiborod M N, Abildstrøm S Z, Borlaug B A, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity[J]. N Engl J Med, 2023, 389(12): 1069-1084. DOI: 10.1056/NEJMoa2306963
|
| [104] |
Lincoff A M, Brown-Frandsen K, Colhoun H M, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes[J]. N Engl J Med, 2023, 389(24): 2221-2232. DOI: 10.1056/NEJMoa2307563
|
| [105] |
Renehan A G, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies[J]. Lancet, 2008, 371(9612): 569-578. DOI: 10.1016/S0140-6736(08)60269-X
|
| [106] |
Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence[J]. Curr Oncol Rep, 2011, 13(1): 71-76. DOI: 10.1007/s11912-010-0139-7
|
| [107] |
Sung H, Siegel R L, Torre L A, et al. Global patterns in excess body weight and the associated cancer burden[J]. CA Cancer J Clin, 2019, 69(2): 88-112. DOI: 10.3322/caac.21499
|
| [108] |
Fulton S, Decarie-Spain L, Fioramonti X, et al. The menace of obesity to depression and anxiety prevalence[J]. Trends Endocrinol Metab, 2022, 33(1): 18-35. DOI: 10.1016/j.tem.2021.10.005
|
| [109] |
Stabouli S, Erdine S, Suurorg L, et al. Obesity and eating disorders in children and adolescents: the bidirectional Link[J]. Nutrients, 2021, 13(12): 4321. DOI: 10.3390/nu13124321
|
| [110] |
Dye L, Boyle N B, Champ C, et al. The relationship between obesity and cognitive health and decline[J]. Proc Nutr Soc, 2017, 76(4): 443-454. DOI: 10.1017/S0029665117002014
|
| [111] |
Tsai C J, Leitzmann M F, Willett W C, et al. Prospective study of abdominal adiposity and gallstone disease in US men[J]. Am J Clin Nutr, 2004, 80(1): 38-44. DOI: 10.1093/ajcn/80.1.38
|
| [112] |
Jiang L, Tian W, Wang Y, et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysis[J]. Joint Bone Spine, 2012, 79(3): 291-297. DOI: 10.1016/j.jbspin.2011.05.015
|
| [113] |
Lv H, Zeng N, Li M, et al. Association between body mass index and brain health in adults: a 16-year population-based cohort and mendelian randomization study[J]. Health Data Sci, 2024, 4: 0087. DOI: 10.34133/hds.0087
|
| [114] |
Sun J, Zeng N, Hui Y, et al. Association of variability in body size with neuroimaging metrics of brain health: a population-based cohort study[J]. Lancet Reg Health West Pac, 2024, 44: 101015.
|
| [115] |
Costantini L, Pasquarella C, Odone A, et al. Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): a systematic review[J]. J Affect Disord, 2021, 279: 473-483. DOI: 10.1016/j.jad.2020.09.131
|
| [116] |
Spitzer R L, Kroenke K, Williams J B, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7[J]. Arch Intern Med, 2006, 166(10): 1092-1097. DOI: 10.1001/archinte.166.10.1092
|
| [117] |
Garner D M, Olmsted M P. Scoring the eating disorder inventory[J]. Am J Psychiatry, 1986, 143(5): 680-681. DOI: 10.1176/ajp.143.5.aj1435680
|
| [118] |
李鲁, 王红妹, 沈毅. SF-36健康调查量表中文版的研制及其性能测试[J]. 中华预防医学杂志, 2002, 36(2): 109-113. DOI: 10.3760/j:issn:0253-9624.2002.02.011
Li L, Wang H M, Shen Y. Development and psychometric tests of a Chinese version of the SF-36 Health Survey Scales[J]. Chin J Prev Med, 2002, 36(2): 109-113. DOI: 10.3760/j:issn:0253-9624.2002.02.011
|
| [119] |
廉东波, 刘晨, 许光中, 等. Moorehead-Ardelt Ⅱ问卷在肥胖患者减重手术后生活质量评估中的应用评价[J]. 中华普通外科杂志, 2021, 36(6): 440-445. DOI: 10.3760/cma.j.cn113855-20210104-00005
Lian D B, Liu C, Xu G Z, et al. Application of Moorehead-Ardelt questionnaire Ⅱ in evaluation of quality of life among patients after bariatric surgery[J]. Chin J Gen Surg, 2021, 36(6): 440-445. DOI: 10.3760/cma.j.cn113855-20210104-00005
|
| [120] |
Kolotkin R L, Crosby R D, Kosloski K D, et al. Development of a brief measure to assess quality of life in obesity[J]. Obes Res, 2001, 9(2): 102-111. DOI: 10.1038/oby.2001.13
|
| [121] |
王征宇, 迟玉芬. 抑郁自评量表(SDS)[J]. 上海精神医学, 1984(2): 71-72.
|
| [122] |
王征宇, 迟玉芬. 焦虑自评量表(SAS)[J]. 上海精神医学, 1984(2): 73-74.
|
| [123] |
彭莉莉, 李进让, 孙建军, 等. Epworth嗜睡量表简体中文版信度和效度评价[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(1): 44-49.
Peng L L, Li J R, Sun J J, et al. Reliability and validity of the simplified Chinese version of Epworth sleepiness scale[J]. Chin J Otorhinolaryngol Head Neck Surg, 2011, 46(1): 44-49.
|
| [124] |
Chung F, Abdullah H R, Liao P. STOP-Bang questionnaire: a practical approach to screen for obstructive sleep apnea[J]. Chest, 2016, 149(3): 631-638. DOI: 10.1378/chest.15-0903
|
| [125] |
Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care[J]. Aliment Pharmacol Ther, 2009, 30(10): 1030-1038. DOI: 10.1111/j.1365-2036.2009.04142.x
|
| [126] |
Wai C T, Greenson J K, Fontana R J, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38(2): 518-526. DOI: 10.1053/jhep.2003.50346
|
| [127] |
Sterling R K, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology, 2006, 43(6): 1317-1325. DOI: 10.1002/hep.21178
|
| [128] |
Angulo P, Hui J M, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology, 2007, 45(4): 846-854. DOI: 10.1002/hep.21496
|
| [129] |
Durrer S D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care[J]. Obes Facts, 2019, 12(1): 40-66. DOI: 10.1159/000496183
|
| [130] |
Vallis T M, MacklinD, Russell-Mayhew S. Canadian adult obesity clinical practice guidelines: effective psychological and behavioural interventions in obesity management[EB/OL]. (2020-08-04)[2024-12-05]. ttps://obesitycanada.ca/guidelines/behavioural.
|
| [131] |
Dalle G R, Sartirana M, El G M, et al. Personalized multistep cognitive behavioral therapy for obesity[J]. Diabetes Metab Syndr Obes, 2017, 10: 195-206. DOI: 10.2147/DMSO.S139496
|
| [132] |
Moraes A, Padovani R, La Scala T C, et al. Cognitive behavioral approach to treat obesity: a randomized clinical trial[J]. Front Nutr, 2021, 8: 611217. DOI: 10.3389/fnut.2021.611217
|
| [133] |
Taylor V H, Sockalingam S, Hawa R, et al. Canadian adult obesity clinical practice guidelines: the roleof mental health in obesity management[EB/OL]. (2020-08-04)[2024-12-05]. https://obesitycanada.ca/guidelines/mentalhealth/.
|
| [134] |
Oppert J M, Bellicha A, Van Baak M A, et al. Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group[J]. Obes Rev, 2021, 22 Suppl 4(Suppl 4): e13273.
|
| [135] |
《运动处方中国专家共识(2023)》专家组. 运动处方中国专家共识(2023)[J]. 中国运动医学杂志, 2023, 42(1): 3-13.
Expert Group on Exercise Prescription in China (2023). Chinese expert consensus on exercise prescription (2023)[J]. Chin J Sports Med, 2023, 42(1): 3-13.
|
| [136] |
Lopez P, Taaffe D R, Galvão D A, et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: a systematic review and meta-analysis[J]. Obes Rev, 2022, 23(5): e13428. DOI: 10.1111/obr.13428
|
| [137] |
Berge J, Hjelmesaeth J, Hertel J K, et al. Effect of aerobic exercise intensity on energy expenditure and weight loss in severe obesity-a randomized controlled trial[J]. Obesity (Silver Spring), 2021, 29(2): 359-369. DOI: 10.1002/oby.23078
|
| [138] |
Chen Y, Chen Z, Pan L, et al. Effect of moderate and vigorous aerobic exercise on incident diabetes in adults with obesity: a 10-Year follow-up of a randomized clinical trial[J]. JAMA Intern Med, 2023, 183(3): 272-275. DOI: 10.1001/jamainternmed.2022.6291
|
| [139] |
中国医疗保健国际交流促进会营养与代谢管理分会, 中国营养学会临床营养分会, 中华医学会糖尿病学分会, 等. 中国超重/肥胖医学营养治疗指南(2021)[J]. 中国医学前沿杂志(电子版), 2021, 13(11): 1-55.
Nutrition and Metabolic Management Branch of China Association for the Promotion of International Exchange in Healthcare, Clinical Nutrition Branch of the Chinese Society of Nutrition, Diabetes Branch of Chinese Medical Association, et al. Guidelines for medical nutrition treatment of overweight/obesity in China (2021)[J]. Chin J Front Med Sci (Electron Version), 2021, 13(11): 1-55.
|
| [140] |
中华人民共和国国家卫生健康委员会办公厅. 成人肥胖食养指南(2024年版)[EB/OL]. [2024-12-05]. http://www.nhc.gov.cn/sps/s7887k/202402/4a82f053aa78459bb88e35f812d184c3.shtm.
Office of the National Health Commission of the People's Republic of China. Adult obesity dietary guidelines (2024 Edition)[EB/OL]. [2024-12-05]. http://www.nhc.gov.cn/sps/s7887k/202402/4a82f053aa78459bb88e35f812d184c3.shtm.
|
| [141] |
中华医学会内分泌学分会, 中华中医药学会糖尿病分会, 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会, 等. 基于临床的肥胖症多学科诊疗共识(2021年版)[J]. 中华肥胖与代谢病电子杂志, 2021, 7(4): 211-226. DOI: 10.3877/cma.j.issn.2095-9605.2021.04.001
Chinese Society of Endocrinology, Diabetes Society of China Association of Chinese Medicine, Chinese Society for Metabolic and Bariatric Surgery, et al. Multidisciplinary clinical consensus on diagnosis and treatment of obesity (2021 edition)[J]. Chin J Obes Metab Dis (Electron Ed), 2021, 7(4): 211-226. DOI: 10.3877/cma.j.issn.2095-9605.2021.04.001
|
| [142] |
中国医疗保健国际交流促进会营养与代谢管理分会, 中国营养学会临床营养分会, 中华医学会糖尿病学分会, 等. 中国糖尿病医学营养治疗指南(2022版)[J]. 中华糖尿病杂志, 2022, 14(9): 881-933. DOI: 10.3760/cma.j.cn115791-20220704-00324
Nutrition and Metabolic Management Branch of China International Exchange and Promotive Association for Medical and Health Care, Clinical Nutrition Branch of Chinese Nutrition Society, Chinese Diabetes Society, et al. Chinese guidelines of medical nutrition therapy in diabetes (2022 edition)[J]. Chin J Diabetes Mellitus, 2022, 14(9): 881-933. DOI: 10.3760/cma.j.cn115791-20220704-00324
|
| [143] |
Del B C, Perna S, Allehdan S, et al. Does the mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials[J]. Nutrients, 2023, 15(10): 2250. DOI: 10.3390/nu15102250
|
| [144] |
Marjot T, Tomlinson J W, Hodson L, et al. Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD[J]. Gut, 2023, 72(8): 1607-1619. DOI: 10.1136/gutjnl-2023-329998
|
| [145] |
Yokose C, McCormick N, Rai S K, et al. Effects of low-fat, Mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors: a secondary analysis of the dietary intervention randomized controlled trial (DIRECT)[J]. Diabetes Care, 2020, 43(11): 2812-2820. DOI: 10.2337/dc20-1002
|
| [146] |
Gao Y, Cui L F, Sun Y Y, et al. Adherence to the dietary approaches to stop hypertension Diet and hyperuricemia: a cross-sectional study[J]. Arthritis Care Res (Hoboken), 2021, 73(4): 603-611. DOI: 10.1002/acr.24150
|
| [147] |
Jensen M D, Ryan D H, Apovian C M, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society[J]. Circulation, 2014, 129(25 Suppl 2): S102-S138.
|
| [148] |
中华人民共和国国家卫生健康委员会办公厅. 成人高脂血症食养指南(2023年版)[EB/OL]. [2024-12-05]. http://www.nhc.gov.cn/sps/s7887k/202301/0e55a01df50c47d9a4a43db026e3afc3/files/252e7bd69d064fc5a00f02fbc64b5e23.pdf.
Office of the National Health Commission of the People's Republic of China. Dietary guidelines for adult hyperlipidemia (2023 edition)[EB/OL]. [2024-12-05]. http://www.nhc.gov.cn/sps/s7887k/202301/0e55a01df50c47d9a4a43db026e3afc3/files/252e7bd69d064fc5a00f02fbc64b5e23.pdf.
|
| [149] |
Lichtenstein A H, Appel L J, Vadiveloo M, et al. 2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association[J]. Circulation, 2021, 144(23): e472-e487.
|
| [150] |
Gardner C D, Vadiveloo M K, Petersen K S, et al. Popular dietary patterns: alignment with American Heart Association 2021 dietary guidance: a scientific statement from the American Heart Association[J]. Circulation, 2023, 147(22): 1715-1730. DOI: 10.1161/CIR.0000000000001146
|
| [151] |
Shi Q, Wang Y, Hao Q, et al. Retracted: pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials[J]. Lancet, 2022, 399(10321): 259-269. DOI: 10.1016/S0140-6736(21)01640-8
|
| [152] |
Henderson K, Lewis, Sloan C E, et al. Effectiveness and safety of drugs for obesity[J]. BMJ, 2024, 384: e072686.
|
| [153] |
Grunvald E, Shah R, Hernaez R, et al. Aga clinical practice guideline on pharmacological interventions for adults with obesity[J]. Gastroenterology, 2022, 163(5): 1198-1225. DOI: 10.1053/j.gastro.2022.08.045
|
| [154] |
Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management[J]. N Engl J Med, 2015, 373(1): 11-22. DOI: 10.1056/NEJMoa1411892
|
| [155] |
Chen K, Chen L, Shan Z, et al. Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study[J]. Diabetes Obes Metab, 2024, 26(2): 690-698. DOI: 10.1111/dom.15360
|
| [156] |
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2022, 10(3): 193-206. DOI: 10.1016/S2213-8587(22)00008-0
|
| [157] |
Mu Y, Bao X, Eliaschewitz F G, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2024, 12(3): 184-195. DOI: 10.1016/S2213-8587(23)00388-1
|
| [158] |
Kosiborod M N, Petrie M C, Borlaug B A, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes[J]. N Engl J Med, 2024, 390(15): 1394-1407. DOI: 10.1056/NEJMoa2313917
|
| [159] |
Jastreboff A M, Aronne L J, Ahmad N N, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022, 387(3): 205-216. DOI: 10.1056/NEJMoa2206038
|
| [160] |
Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial[J]. JAMA, 2024, 332(7): 551-560. DOI: 10.1001/jama.2024.9217
|
| [161] |
American Diabetes Association Professional Practice Committee. Erratum. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes care 2024;47(Suppl. 1): S158-S178[J]. Diabetes Care, 2024, 47(7): 1238.
|
| [162] |
Prillaman M. Obesity drugs aren't always forever. What happens when you quit?[J]. Nature, 2024, 628(8008): 488-490. DOI: 10.1038/d41586-024-01091-8
|
| [163] |
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial[J]. JAMA, 2021, 325(14): 1414-1425. DOI: 10.1001/jama.2021.3224
|
| [164] |
Wilding J, Batterham R L, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension[J]. Diabetes Obes Metab, 2022, 24(8): 1553-1564. DOI: 10.1111/dom.14725
|
| [165] |
Aronne L J, Sattar N, Horn D B, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial[J]. JAMA, 2024, 331(1): 38-48. DOI: 10.1001/jama.2023.24945
|
| [166] |
Wilding J, Batterham R L, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity[J]. N Engl J Med, 2021, 384(11): 989-1002. DOI: 10.1056/NEJMoa2032183
|
| [167] |
Mirzai S, Carbone S, Batsis J A, et al. Sarcopenic obesity and cardiovascular disease: an overlooked but high-risk syndrome[J]. Curr Obes Rep, 2024, 13(3): 532-544. DOI: 10.1007/s13679-024-00571-2
|
| [168] |
Chen M, Jia Q, Chen Y, et al. A meta-analysis of bariatric surgery in patients with obesity and polycystic ovary syndrome[J]. Asian J Surg, 2024, 47(12): 5083-5087. DOI: 10.1016/j.asjsur.2024.04.003
|
| [169] |
Gu C, Bernstein N, Mittal N, et al. Potential therapeutic targets in obesity, sleep apnea, diabetes, and fatty liver disease[J]. J Clin Med, 2024, 13(8): 2231. DOI: 10.3390/jcm13082231
|
| [170] |
Schiavon C A, Cavalcanti A B, Oliveira J D, et al. Randomized trial of effect of bariatric surgery on blood pressure after 5 years[J]. J Am Coll Cardiol, 2024, 83(6): 637-648. DOI: 10.1016/j.jacc.2023.11.032
|
| [171] |
Ghiassi S, Nimeri A, Aleassa E M, et al. American Society for Metabolic and Bariatric Surgery Position statement on one-anastomosis gastric bypass[J]. Surg Obes Relat Dis, 2024, 20(4): 319-335. DOI: 10.1016/j.soard.2023.11.003
|
| [172] |
Brito J P, Montori V M, Davis A M. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations[J]. JAMA, 2017, 317(6): 635-636. DOI: 10.1001/jama.2016.20563
|
| [173] |
Di Lorenzo N, Antoniou S A, Batterham R L, et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP[J]. Surg Endosc, 2020, 34(6): 2332-2358. DOI: 10.1007/s00464-020-07555-y
|
| [174] |
Eisenberg D, Shikora S A, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery[J]. Obes Surg, 2023, 33(1): 3-14. DOI: 10.1007/s11695-022-06332-1
|
| [175] |
Kow L, Sharaiha R Z, O'Kane M, et al. Methodology and results of a joint IFSO-WGO delphi survey of 94 intercontinental, interdisciplinary experts in obesity management[J]. Obes Surg, 2023, 33(11): 3337-3352. DOI: 10.1007/s11695-023-06757-2
|
| [176] |
中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和代谢病外科专家工作组. 中国肥胖及代谢疾病外科治疗指南(2024版)[J]. 中国实用外科杂志, 2024, 44(8): 841-849.
Chinese Society of Thyroid and Metabolism Surgery, Chinese Society of Surgery, Chinese Medical Association, Chinese Society for Metabolic & Bariatric Surgery, Chinese College of Surgeons, Chinese Medical Doctor Association. Chinese clinical guidelines for the surgery of obesity and metabolic disorders (2024 edition)[J]. Chin J Pract Surg, 2024, 44(8): 841-849.
|
| [177] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(上)[J]. 中国实用内科杂志, 2021, 41(8): 668-695.
Diabetes Branch of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) (Part 1)[J]. Chin J Pract Intern Med, 2021, 41(8): 668-695.
|
| [178] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(下)[J]. 中国实用内科杂志, 2021, 41(9): 757-784.
Diabetes Branch of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) (Part 2)[J]. Chin J Pract Intern Med, 2021, 41(9): 757-784.
|
| [179] |
Mechanick J I, Apovian C, Brethauer S, et al. Clinial practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures-2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists-executive summary[J]. Endocr Pract, 2019, 25(12): 1346-1359.
|
| [180] |
中国研究型医院学会糖尿病与肥胖外科专业委员会. 减重代谢外科围术期处理专家共识(2019版)[J]. 中华消化外科杂志, 2019, 18(9): 811-821. DOI: 10.3760/cma.j.issn.1673-9752.2019.09.001
Chinese Research Hospital Association, Society for Diabetes and Bariatric Surgery. Expert consensus on perioperative management in bariatric and metabolic surgery[J]. Chin J Dig Surg, 2019, 18(9): 811-821. DOI: 10.3760/cma.j.issn.1673-9752.2019.09.001
|
| [181] |
杨华, 张鹏, 董志勇, 等. 中国肥胖代谢外科手术方式推荐立场声明[J]. 中华肥胖与代谢病电子杂志, 2021, 7(1): 8-12. DOI: 10.3877/cma.j.issn.2095-9605.2021.01.002
Yang H, Zhang P, Dong Z Y, et al. Position statement on recommendations of surgical procedures in metabolic and bariatric surgery of China[J]. Chin J Obes Metab Dis (Electron Ed), 2021, 7(1): 8-12. DOI: 10.3877/cma.j.issn.2095-9605.2021.01.002
|
| [182] |
张鹏, 张忠涛. 中国减重代谢外科主流手术方式的科学评价[J]. 中华消化外科杂志, 2020, 19(11): 1145-1150. DOI: 10.3760/cma.j.cn115610-20200908-00608
Zhang P, Zhang Z T. Rational assessment of mainstream bariatric and metabolic surgical procedures performed in China[J]. Chin J Dig Surg, 2020, 19(11): 1145-1150. DOI: 10.3760/cma.j.cn115610-20200908-00608
|
| [183] |
Mechanick J I, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures–2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists[J]. Obesity (Silver Spring), 2020, 28(4): O1-O58.
|
| [184] |
中华医学会肠外肠内营养学分会营养与代谢协作组, 北京协和医院减重多学科协作组. 减重手术的营养与多学科管理专家共识[J]. 中华外科杂志, 2018, 56(2): 81-90.
Nutrition and Metabolism Collaboration of Chinese Society for Parenteral and Enteral Nutrition, Bariatric Multidisciplinary Team of Peking Union Medical College Hospital. The consensus on nutritional and multi-disciplinary management for bariatric surgery[J]. Chin J Surg, 2018, 56(2): 81-90.
|
| [185] |
Xu T, Wang C, Zhang H, et al. Timing of maximal weight reduction following bariatric surgery: a study in Chinese patients[J]. Front Endocrinol (Lausanne), 2020, 11: 615. DOI: 10.3389/fendo.2020.00615
|
| [186] |
中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 肥胖代谢外科修正手术东亚专家共识(2018)[J]. 中华肥胖与代谢病电子杂志, 2018, 4(1): 1-4. DOI: 10.3877/cma.j.issn.2095-9605.2018.01.001
Obesity and diabetes Surgeons Committee of Surgeons Branch of Chinese Medical Doctor Association. East Asian consensus on revisional metabolic and bariatric surgery (2018)[J]. Chin J Obes Metab Dis (Electron Ed), 2018, 4(1): 1-4. DOI: 10.3877/cma.j.issn.2095-9605.2018.01.001
|
| [187] |
Firkins S A, Chittajallu V, Flora B, et al. Utilization of anti-obesity medications after bariatric surgery: analysis of a large national database[J]. Obes Surg, 2024, 34(5): 1415-1424. DOI: 10.1007/s11695-024-07181-w
|
| [188] |
中华中医药学会《中医体重管理临床指南》专家组, 广东省针灸学会肥胖专病联盟. 肥胖症中医诊疗方案专家共识[J]. 北京中医药大学学报, 2022, 45(8): 786-794. DOI: 10.3969/j.issn.1006-2157.2022.08.006
Expert Group on Clinical Guidelines for Traditional Chinese Medicine Weight Management of the Chinese Society of Traditional Chinese Medicine, Obesity Alliance of Acupuncture and Moxibustion and Moxibustion Society of Guangdong Province. Expert consensus on diagnosis and treatment of obesity in TCM[J]. J Beijing Univ Tradit Chin Med, 2022, 45(8): 786-794. DOI: 10.3969/j.issn.1006-2157.2022.08.006
|
| [189] |
中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会儿童保健学组, 中华医学会儿科学分会临床营养学组, 等. 中国儿童肥胖诊断评估与管理专家共识[J]. 中华儿科杂志, 2022, 60(6): 507-515. DOI: 10.3760/cma.j.cn112140-20220112-00043
The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association, the Subspecialty Group of Child Health Care, the Society of Pediatrics, Chinese Medical Association, the Subspecialty Group of Clinical Nutrition, the Society of Pediarics, Chinese Medical Association, et al. Expert consensus on diagnosis, assessment, and management of obesity in Chinese children[J]. Chin J Pediatr, 2022, 60(6): 507-515. DOI: 10.3760/cma.j.cn112140-20220112-00043
|
| [190] |
Ruiz L D, Zuelch M L, Dimitratos S M, et al. Adolescent obesity: Diet quality, psychosocial health, and cardiometabolic risk factors[J]. Nutrients, 2019, 12(1): 43. DOI: 10.3390/nu12010043
|
| [191] |
Fox C K, Gross A C, Bomberg E M, et al. Severe obesity in the pediatric population: current concepts in clinical care[J]. Curr Obes Rep, 2019, 8(3): 201-209. DOI: 10.1007/s13679-019-00347-z
|
| [192] |
中国儿童青少年身体活动指南制作工作组, 张云婷, 马生霞, 等. 中国儿童青少年身体活动指南[J]. 中国循证儿科杂志, 2017, 12(6): 401-409. DOI: 10.3969/j.issn.1673-5501.2017.06.001
Chinese Children and Adolescents Physical Activity Guidelines Production Working Group, Zhang Y T, Ma S X, et al. Guidelines for physical activity of children and adolescents in China[J]. Chin J Evid Based Pediatr, 2017, 12(6): 401-409. DOI: 10.3969/j.issn.1673-5501.2017.06.001
|
| [193] |
中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 中国儿童和青少年肥胖症外科治疗指南(2019版)[J]. 中华肥胖与代谢病电子杂志, 2019, 5(1): 3-9. DOI: 10.3877/cma.j.issn.2095-9605.2019.01.001
Obesity and diabetes Surgeons Committee of Surgeons Branch of Chinese Medical Doctor Association. The clinical guideline for surgical treatment of childhood and adolescent obesity in China (2019 Edition)[J]. Chin J Obes Metab Dis (Electron Ed), 2019, 5(1): 3-9. DOI: 10.3877/cma.j.issn.2095-9605.2019.01.001
|
| [194] |
Lachal J, Orri M, Speranza M, et al. Qualitative studies among obese children and adolescents: a systematic review of the literature[J]. Obes Rev, 2013, 14(5): 351-368. DOI: 10.1111/obr.12010
|
| [195] |
Barry M J, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care[J]. N Engl J Med, 2012, 366(9): 780-781. DOI: 10.1056/NEJMp1109283
|
| [196] |
Shared decision making[M]. London: National Institute for Health and Care Excellence, 2021.
|
| [197] |
AHRQ. The SHARE approach[EB/OL]. [2024-12-05]. https://www.ahrq.gov/health-literacy/professional-training/shared-decision/index.html.
|
| 1. |
刘少壮 ，赵世刚 ，王勇 ，朱利勇 ，董志勇. 减重代谢手术治疗肥胖症合并多囊卵巢综合征中国专家共识（2025年版）. 中国实用外科杂志. 2025(02): 156-159+164 .
| |
| 2. |
胡三元 ，刘少壮 ，赵世刚 ，王勇 ，朱利勇 ，董志勇. 减重代谢手术治疗肥胖症合并多囊卵巢综合征中国专家共识（2025年版）. 中国普通外科杂志. 2025(02): 183-189 .
| |
| 3. |
袁慧娟，杨俊朋，邓欣如，衡红艳，刘亚雷，杨雪丽. 肠道微生态制剂及菌群移植治疗肥胖症专家共识. 中华实用诊断与治疗杂志. 2025(03): 193-202 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: